Home Compare MRVL vs ZEAL.CO
Stock Comparison · Structural lead, mixed market

Marvell Technology vs Zealand Pharma A/S: Which Stock Looks Stronger in 2026?

Zealand Pharma A/S holds the cleaner structural position, with the lead spread across profitability and growth. Marvell Technology does not offset that deficit through any equally strong structural edge elsewhere. In the market, Marvell Technology carries the stronger setup — intact trend against Zealand Pharma A/S's broken trend. That leaves a split case: the structural lead stays with Zealand Pharma A/S, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in profitability, but growth adds another real layer to the result. Zealand Pharma A/S leads by 29 points on the overall comparison score.

Trajectory Similarity
0.70
Moderately similar
Peer-set rank: #3
within Marvell Technology, Inc.'s functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

The clearest structural overlap shows up in capital structure.

Similarity drivers
capital structure
What reduces the match
recent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
MRVL
Marvell Technology, Inc.
55
Peer-Score
Signal qualityHigh
vs
ZEAL.CO
Zealand Pharma A/S
84
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: MRVL vs ZEAL.CO Profitability 60 100 Stability 31 36 Valuation 62 88 Growth 61 100 MRVL ZEAL.CO
Gap Ranking
#1 Profitability +40
#2 Growth +39
#3 Valuation +26
#4 Stability +5
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for MRVL and ZEAL.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer MRVLZEAL.CO Relative valuation Structural strength

Zealand Pharma A/S looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both rank well on profitability, but Zealand Pharma A/S still holds a clear edge.
Growth
On growth, the same pattern holds: both are strong, but Zealand Pharma A/S still leads clearly.
Profitability — Dominant Gap
MRVL
60
ZEAL.CO
100
Gap+40in favour of ZEAL.CO

Capital efficiency adds support, with a 4978-point ROIC advantage.

What keeps the gap from being one-sided

On the market side, Marvell Technology carries the stronger trend while Zealand Pharma A/S's trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

The lead is built on both profitability and growth, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the MRVL vs ZEAL.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-growth comparisons

Explore how MRVL and ZEAL.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.